3 top pharma stocks immune to Brexit: AstraZeneca plc, Shire plc and Hikma Pharmaceuticals plc

Bilaal Mohamed looks at three pharmaceuticals plays that could offer shelter from Brexit panic: AstraZeneca plc (LON: AZN), Shire plc (LON: SHP) and Hikma Pharmaceuticals plc (LON: HIK).

| More on:

The content of this article was relevant at the time of publishing. Circumstances change continuously and caution should therefore be exercised when relying upon any content contained within this article.

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More.

Today I’ll be discussing the outlook for FTSE 100 pharmaceutical giants AstraZeneca, Shire and Hikma Pharmaceuticals. Shares in all three companies have outperformed the market since the vote to leave the EU, but are they likely to be sound investments in the longer term?

Brexit-resistant drugmaker

Anglo-Swedish drugs giant AstraZeneca (LSE: AZN) has won approval for a new antibiotic in the fight against drug resistance. The company was granted marketing authorisation by the European Commission for its Zavicefta treatment, a combination antibiotic developed in response to the increasingly urgent need for new drugs to treat serious infections that are becoming increasingly resistant to antibiotics.

Shares in the FTSE 100 stalwart have rallied over the past week or so, with impressive gains since the UK’s decision to leave the EU. But the market is expecting Astra to report a 14% dip in earnings for the full year to £3.4bn on significantly lower revenues, and I believe the shares look expensive at 17 times earnings. However, attractions remain for income-seekers with dividend payouts yielding well over 4% and covered almost one-and-a-half times by forecast earnings.

Unexpected boost

Dublin-based pharmaceuticals firm Shire (LSE: SHP) received an unexpected boost recently when a drug that had failed tests to treat a form of infant blindness instead showed positive effects on severe complications relating to lung and brain damage. The company hopes to start discussions with regulators about a phase-three clinical programme focusing on clinically relevant complications of prematurity later this year.

Like its larger rival AstraZeneca, Shire has outperformed the rest of the index since the vote to leave the EU, as investors have flocked to defensive sectors like pharmaceuticals and utilities. Analysts are talking about an impressive 77% rise in earnings this year, followed by a further 17% next year, leaving the shares trading on a reasonable P/E rating of 14 for 2017. I believe the shares still offer good value given the strong growth outlook.

Back to the big league

A welcome back to the FTSE 100 for Hikma Pharmaceuticals (LSE: HIK), which re-joined the top index recently after being relegated to the FTSE 250 in March following a share price slump at the start of the year. The drugmaker received a further boost recently after winning a court case dismissing claims of a patent infringement involving a rival’s gout treatment.

The son of the firm’s founder and current chief executive Said Darwazah celebrated the court case win by purchasing 150,000 shares worth £3.3m, along with two other directors who also bought 150,000 shares on the same day. Hikma’s shares have gained 21% in just three months and look to be trading at a premium 30 times forecast earnings for the year to December. I would put the stock on my watch list and wait for a better entry point before dipping into this quality pharmaceuticals play.

Should you invest, the value of your investment may rise or fall and your capital is at risk. Before investing, your individual circumstances should be assessed. Consider taking independent financial advice.

Bilaal Mohamed has no position in any shares mentioned. The Motley Fool UK has recommended AstraZeneca and Hikma Pharmaceuticals. We Fools don't all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors.

More on Investing Articles

Investing Articles

Should I still be cautious about Rolls-Royce shares?

Rolls-Royce shares are flying. But is now the time for this Fool to open a position? Here, he explains why…

Read more »

Group of young friends toasting each other with beers in a pub
Investing Articles

Is the Diageo share price coiled to rebound?

Christopher Ruane explains why he remains bullish about the long-term outlook for the Diageo share price and would happily invest…

Read more »

Young Asian woman holding a cup of takeaway coffee and folders containing paperwork, on her way into the office
Investing Articles

How I could make a 10% yield for high passive income a reality

Jon Smith explains how he can target high passive income from top-yielding stocks, including one specific example he'd consider.

Read more »

Investing Articles

I’d buy 1,784 shares of this FTSE 100 stock to target £350 of monthly passive income

Muhammad Cheema takes a look at how British American Tobacco shares, with a dividend yield of 10.1%, can generate a…

Read more »

White female supervisor working at an oil rig
Investing Articles

1 ex-FTSE 100 stock that I think will get promoted soon

Jon Smith flags up an energy stock that used to be in the FTSE 100 and currently has strong momentum…

Read more »

Shot of a young Black woman doing some paperwork in a modern office
Investing Articles

With an 8% dividend yield, I think this undervalued FTSE stock is a no-brainer buy

With an impressive yield and good track record of payments, Mark David Hartley is considering adding this promising FTSE share…

Read more »

Passive income text with pin graph chart on business table
Investing Articles

£9,500 in savings? Here’s how I’d try to turn that into £1,809 a month of passive income

Investing a relatively small amount into high-yielding stocks and reinvesting the dividends paid can generate significant passive income over time.

Read more »

Businesswoman analyses profitability of working company with digital virtual screen
Investing Articles

Dividend star Legal & General’s share price is still marked down, so should I buy more?

Legal & General’s share price looks very undervalued against its peers. But it pays an 8%+ dividend yield, and has…

Read more »